Merck Out-Licenses Gene Therapy Assets To FKD Therapies

Finland's FKD Therapies set up to exploit Merck & Co's gene therapy assets, and expects to start Phase II trials of a bladder cancer therapeutic in 2012.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet